Citigroup Inc Kinnate Biopharma Inc. Transaction History

Citigroup Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$1.38 - $3.31 $579,317 - $1.39 Million	419,795 Added 53138.61%	420,585 $588,000
Q2 2023 Aug 10, 2023	BUY	$2.33 - $6.84 $664 - $1,949	285 Added 56.44%	790 $2,000
Q1 2023 May 11, 2023	SELL	$3.46 - $7.98 $837 - $1,931	-242 Reduced 32.4%	505 $3,000
Q4 2022 Feb 09, 2023	SELL	$5.26 - $12.19 $1,083 - $2,511	-206 Reduced 21.62%	747 $4,000
Q3 2022 Nov 10, 2022	SELL	$9.86 - $15.76 $17,787 - $28,431	-1,804 Reduced 65.43%	953 $11,000
Q2 2022 Aug 10, 2022	SELL	$7.43 - $13.0 $15,647 - $27,378	-2,106 Reduced 43.31%	2,757 $35,000
Q1 2022 May 12, 2022	SELL	$7.73 - $17.99 $30,371 - $70,682	-3,929 Reduced 44.69%	4,863 $55,000
Q4 2021 Feb 10, 2022	BUY	$16.5 - $25.48 $82,401 - $127,247	4,994 Added 131.49%	8,792 $156,000
Q3 2021 Nov 10, 2021	BUY	$17.81 - $24.87 $67,642 - $94,456	3,798 New	3,798 $87,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.